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ABSTRACT
Objectives: The objective of this study was to review and
analyze the use of health-related quality of life (HRQL)
and other patient-reported outcome (PRO) evaluations
for the approval of new pharmaceutical products by the
European Medicines Agency (EMEA).
Methods: All published EMEA guidance documents and
regulatory information for products authorized at the
EMEA and appearing in the European Public Assessment
Report (EPAR) database between 1995 and 2003 were
examined for reference to HRQL and other PROs.
Results: More than half of the guidance documents for
clinical investigation of pharmaceutical products in spe-
ciﬁc disease areas included reference to HRQL or other
PROs. Guidance notes for 10 conditions indicated PROs
can serve as primary endpoints in clinical trials, among
which three included HRQL outcomes. The review of
EPAR documentation uncovered HRQL and other PRO
data for 34% of the drugs registered during the period of
the review, with cancer-related treatments most frequently
including PRO data. There was a trend toward increasing
HRQL and other PRO claims in regulatory documents of
pharmaceutical products in recent years, with the propor-
tion exceeding 30% from 1999 to 2003.
Conclusions: There is further scope for health outcomes
researchers and regulatory decision-makers to contribute
to the more efﬁcient utilization of PROs and HRQL out-
comes. Health researchers need to better justify the inclu-
sion of these outcomes in clinical trials and highlight the
added value of PRO data; while the regulators should
develop harmonized procedures and capacities to ade-
quately appraise the submitted information.
Keywords: drug authorization, EMEA, health-related
quality of life, patient perspective, patient-reported out-
come, regulatory issues.
Introduction
In the European Union (EU), both the European
Commission (EC) and the national health authori-
ties of the EU member states have the authority to
register medicinal products. In an effort to harmo-
nize the review process across member states, the
EC established a formal, centralized authorization
procedure in 1995, delegating its certifying power
to the European Medicines Agency (EMEA). The
EMEA consists of members or delegates from the
participating national health authorities and serves
as a coordinating body, bringing national experts
together for the centralized evaluation process.
Within the EMEA, the pan-European Committee
for Medicinal Products for Human Use (CHMP) is
responsible for producing guidelines and making
decisions about the authorization of most medicinal
products for human use (Before 2004, it was called
as the Committee for Proprietary Medicinal Prod-
ucts—CPMP). The CHMP’s work is, in turn,
supported by several working parties, such as the
Efﬁcacy Working Party (EWP). With the increasing
emphasis on harmonization across the EU and
ongoing interest in placing all drug approvals
through a centralized review process [1], the impor-
tance of the EMEA continues to increase.
The EMEA was established at a time when
health-related quality of life (HRQL) and other
types of patient-reported outcomes (PRO) were
emerging as important components of the evalua-
tion of new pharmaceutical products worldwide.
Although scientiﬁc evidence had been accumulating
on the usefulness of validated measures of self-
reported health outcomes in evaluating a broad
range of health care interventions, relatively little
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was known about how this type of information was
incorporated into the drug regulatory decision-
making process [2,3]. For this reason, the EMEA
began the authorization process without a deﬁned
approach for evaluating HRQL and other PRO
data.
Despite the absence of speciﬁc guidance docu-
ments on HRQL and other PROs, and of any
demand from the EMEA, pharmaceutical compa-
nies have elected to include these outcomes in clin-
ical trials and submit these data to the EMEA as
part of the review process. The ﬁrst case where
HRQL data appeared in product regulatory docu-
ments was docetaxel, one of three products regis-
tered at the EMEA during its ﬁrst year of operation.
Docetaxel is indicated for the treatment of locally
advanced or metastatic breast cancer. Evidence for
impact of the drug on HRQL, measured by the
European Organization for Research on Treatment
of Cancer (EORTC) quality of life questionnaire,
was provided from a large phase III study in which
docetaxel was used in combination with doxoru-
bicin. HRQL results were discussed both under efﬁ-
cacy and safety sections of the Scientiﬁc Discussion
document. In terms of efﬁcacy, the document stated
that no difference could be observed in HRQL
between the two patient groups, indicating no
adverse effects of treatment. With respect to safety
considerations, the document indicated that the sta-
bility of HRQL during treatment reﬂected that drug
toxicity was manageable in both treatment arms.
These ﬁndings also appeared in the summary of
product characteristics (SPC) document, stating,
“In both arms, quality of life measured by the
EORTC questionnaire was comparable and stable
during treatment and follow-up.” This early expe-
rience with HRQL in the authorization process
serves as a baseline for a review of the use of HRQL
in regulatory submissions in Europe between 1995
and 2003.
A previous review by Apolone et al. [4], exam-
ined the EMEA’s recommendations on the use of
HRQL data in clinical trials, and found that HRQL
was discussed as a potential efﬁcacy endpoint in
several of the guidelines. The authors concluded
that the recommendations were vague and incon-
sistent across disease areas. The objective of this
study was to update the information on HRQL and
expand the work by providing an in-depth review
and analysis of HRQL and other PRO information
in EMEA guidance documents and authorizations
of medicinal products performed between 1995
and 2003. This review forms the basis for recom-
mendations on future efforts to bridge health
outcomes research and European drug regulatory
decision-making.
Methods
This study reviewed the role of HRQL outcomes
and other PROs in the European centralized regu-
latory process. Although there is no one single def-
inition of PROs accepted by all researchers, broad
agreement exists on a number of its key character-
istics. We adopted a recently published deﬁnition of
PROs as recommended by an international harmo-
nization task force [5]. According to this deﬁnition
PROs represent the patient’s report of a health con-
dition and its treatment. PROs are inherently sub-
jective and they provide a unique contribution to
the drug development process. HRQL is one of the
several types of PROs and represents the patient’s
evaluation of the impact of a health condition and
its treatment on daily life, well-being and function-
ing. HRQL is of multidimensional nature, with type
and number of dimensions varying across diseases.
Other PROs include patient-reported symptoms,
preference, satisfaction with treatment, functional
status, disability, and other outcomes.
During the review, the above deﬁned broad def-
inition of PROs was applied to identify products for
detailed review. Patient-reported symptoms were
included only if they were reported to be collected
in a systematic way, that is, from each subject using
standardized procedures during which the patient
rated his or her health status. When relevant, we
also included outcomes reported by proxy respond-
ents. The type of PRO response scale or the number
of items used in the PRO evaluation was not an
inclusion or exclusion criteria. Those products for
which the information in the regulatory document
was insufﬁcient to decide whether a PRO was actu-
ally measured were not counted among those with
PRO data.
Search Strategy
A systematic manual search was performed on guid-
ance documents and product level regulatory docu-
ments published on the EMEA’s Web site. The time
frame of the review was the period between 1995
and the end of 2003. The documents were read indi-
vidually to identify all PROs. Electronic searches on
selected PROs (i.e., quality of life, health status, dis-
ability, well-being, patient satisfaction) served to
check the manual review. Given the varied use of
different terms for PROs in EMEA guidance docu-
ments, we thought that the manual review would
provide the most comprehensive information.
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Systematic searches were performed on publicly
available ofﬁcial regulatory documents at two
main levels: (1) general and disease-speciﬁc guid-
ance documents; and (2) product-level regulatory
documents.
Guidance documents. EMEA/CHMP disease/drug-
related guidance documents provide recommenda-
tions for submissions related to a particular disease
(e.g., acute stroke) or medicinal group (e.g.,
antiarrhythmics). These documents are normally
prepared by the Efﬁcacy Working Party and are
then reviewed and endorsed by the CHMP. There
are three main types of guidance documents at this
level: Concept papers, Points to consider, and
Guidelines. These documents are hierarchical in
terms of their developmental status, the scientiﬁc
evidence on which they are based, and the expecta-
tions for compliance. Thus, recommendations
included in the guidelines have the strongest impact
on clinical trials while those included in the concept
papers have the lowest impact. The status and the
content of guidance documents change over time
through development and updating.
For this study, all general and disease/drug-
related guidance documents on regulatory clinical
trials developed through the EMEA’s Committee
for Proprietary Medicinal Products with mention
of HRQL and PRO data were identiﬁed. General
guidance documents are relevant to drugs across all
diseases while disease/drug-related guidance docu-
ments on clinical trials provide recommendations
speciﬁc or unique to the stated disease or therapeu-
tic indication or groups of medicinal products.
Health-related quality of life and other PRO data
were summarized along several dimensions: the
type of HRQL or other PRO data mentioned in the
recommendations, whether these data were recom-
mended as primary or secondary endpoints, and
whether there were any speciﬁc instruments men-
tioned or recommended for use in clinical studies.
Product-level documents. The review also included
a search for HRQL and other PRO evaluation data
in product-level regulatory documents. The Euro-
pean Public Assessment Report (EPAR), the pub-
lished documentation of product-level regulatory
information published by the EMEA, was reviewed
for all product-level regulatory information for
pharmaceutical products registered with the EMEA
between 1995 and 2003. Four types of product-
related EPAR documents were examined:
• Scientiﬁc Discussions: a detailed summary of
the reviewed material submitted by the manu-
facturers to the EMEA to obtain marketing
authorization for that product.
• Summary of Product Characteristics: a des-
cription of  the  product  for  the  information
of physicians as published in national drug
compendia.
• Package Leaﬂets: information intended for the
patient.
• Abstracts: a one-page document that summa-
rizes the key ﬁndings of the evaluation process
and the decision on granting authorization for
the general public.
To interpret the results of this component of the
review, it is important to understand the legal and
regulatory background on the intended content and
use of these documents.
The Scientiﬁc Discussion is the most detailed
description of the scientiﬁc evidence from the
regulatory evaluation of each new product. The
Scientiﬁc Discussion contains commentary made
by the CHMP. The purpose of the Scientiﬁc Dis-
cussion is to achieve transparency of the decision-
making  process  and  to  describe  to  the  public
how decisions were made about granting a mar-
keting authorization for a new pharmaceutical
product.
As outlined in the European Commission’s
Guideline on Summary of Product Characteristics
[4], the objective of the SPC is to provide “informa-
tion for health professionals on how to use the
medicinal product safely and effectively.” After
approval is granted by the EMEA, the SPC serves as
the description of the product in national drug com-
pendia. According to the guidance [6] the SPC is to
include speciﬁc pharmacologic and manufacturer-
related information. Clinical efﬁcacy can only be
included in the “pharmacodynamic properties” sec-
tion of the SPC but generally “no information is
expected.” The guideline, however, states that in
some cases, such as in new therapeutic areas, “main
results (statistically compelling) . . . could be men-
tioned here in condensed form.” This is compulsory
for medicinal products approved under exceptional
circumstances.
The Package Leaﬂet contains information
intended for the patient. This summary information
is provided to the patient on obtaining the medica-
tion. According to the ofﬁcial requirements [7,8],
the package leaﬂet shall be based on information
provided by the SPC. As a general approach, no efﬁ-
cacy data are to be included in the package leaﬂet.
Nevertheless, in accordance with Directive 92/27/
EEC [8], the package leaﬂet may include “. . . other
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information compatible with the summary of
product characteristics, which is useful for health
education, to the exclusion of any element of a pro-
motional nature.”
A systematic search was performed on the Scien-
tiﬁc Discussion of each product registered at the
EMEA between 1995 and 2003, using the EPAR
documents and the search terms listed above. The
purpose of this phase of the review was to deter-
mine the extent to which HRQL and other PRO
data were considered during the decision-making
process, as reﬂected in the Scientiﬁc Discussion
document. It is important to note that information
presented in the Scientiﬁc Discussion reﬂects data
that were considered or accepted for consideration
during the decision-making process, rather than all
of the information submitted for review. It is possi-
ble therefore that HRQL or other PRO data were
submitted, but do not appear in the Scientiﬁc Dis-
cussion of the product.
If HRQL and other PRO data were reported in
the Scientiﬁc Discussion, a further review was per-
formed on the SPC, the package leaﬂet, and the
abstract to determine how the HRQL or PROs were
measured, presented, interpreted, and commented.
Although, based on the above described regulations
the content of the SPC and the package leaﬂet
should not normally include any efﬁcacy data, it
was still interesting to study how frequently and in
what ways HRQL is and other PROs are presented
in these documents.
Validation
Results of the systematic review of published regu-
latory documents were validated through semistruc-
tured interview with individuals employed by the
EMEA. The interview centered around ﬁve main
topics: conceptual deﬁnition; decision-making proc-
ess, organization, and the role and place of HRQL
data; currently published ofﬁcial EMEA/CHMP
recommendations on HRQL data and their impact
on submissions; comparisons with the Food and
Drug Administration (FDA); and opinion, future
plans. The objective of the semistructured interview
was to interpret and validate the ﬁndings of the sys-
tematic review of regulatory documents. All infor-
mation gained through interview is presented as a
summary and the names of the participants will
remain conﬁdential.
Numeric Summary
To assess trends over time, the number of registered
products with HRQL and other PRO data were
summarized by year.
Results
Guidance Documents
General. During the time period of this review
(1995–2003), no general guidance document was
published by the EMEA on HRQL or other PRO
evaluation in clinical trials performed for regulatory
purposes.
One general guidance document was published
that included recommendations on HRQL measure-
ment: the International Conference on Harmoniza-
tion (ICH) guidance document on statistical
principles for clinical trials [9,10]. This document
suggests that the primary clinical endpoint in any
trial be the variable capable of providing the most
clinically relevant and convincing evidence directly
related to the primary objective of the study, which
is generally to evaluate treatment efﬁcacy. Safety/
tolerability may serve as the primary variable, and
will always be an important consideration. The
guidance document also included the following
comment: “measurement related to quality of life
and health economics are further potential primary
variables.” No recommendations were provided
speciﬁc to the measurement of HRQL. In general,
the guidance recommended that the selection of the
primary variable reﬂect the accepted norms and
standards in the relevant ﬁeld of research. There
should be sufﬁcient evidence that the primary vari-
able can provide a valid and reliable measure of
some clinically relevant and important treatment
beneﬁt in the patient population described by the
inclusion and exclusion criteria.
Semistructured interviews with representatives of
the EMEA not only conﬁrmed that there were no
general guidance documents on HRQL or PROs,
but indicated that the EMEA had not adopted any
explicit deﬁnitions of HRQL for use during the
review process, because of the perceived lack of a
consensus deﬁnition for HRQL in the scientiﬁc
community. Accordingly, the EMEA accepts deﬁni-
tions of HRQL on a submission-by-submission
basis. The primary concern of the EMEA is the use
of solid scientiﬁc methodology and robustness with
each individual submission. Research should be
designed to demonstrate that drugs are safe, efﬁca-
cious, and of good quality. The selection of any out-
comes, including HRQL and PROs, should be
justiﬁed in these terms; the design and implementa-
tion of the study should be sound.
Disease-speciﬁc guidance documents. Table 1 sum-
marizes the inclusion of HRQL and other PRO data
in disease/drug-related guidance documents issued
by the EMEA from 1995 to 2003. Of the 57 docu-
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ments issued, more than half (53%) included
recommendations or statements on the use of
HRQL and other PROs in clinical investigations of
medicinal products. Four of the identiﬁed guidance
documents (i.e., sepsis, social anxiety disorder,
antiarrhythmics, and acute cardiac failure) sug-
gested that HRQL is an important aspect of the dis-
ease, treatment or side effects, but did not contain
any explicit recommendations on the use of such
measurement in clinical evaluations. An additional
review of guidance documents on biotechnology
and blood products revealed only one document
referring to HRQL as relevant aspect of treatment
[11], although had no speciﬁc recommendations on
its evaluation.
Although slightly more than half of the guidance
documents included statements or recommenda-
tions on HRQL or PRO data, almost half of the
documents did not. There was no clear pattern in
the difference between those diseases/drug groups
for which recommendations included HRQL and
other PROs data and those diseases which did not.
In fact, many of the documents that did not include
mention of HRQL data were in chronic diseases,
such as diabetes, depression, and schizophrenia,
where new treatments could have a substantial im-
pact on patient HRQL. The impact of these chronic
illnesses on HRQL has been demonstrated, and
there are instruments available for assessing HRQL
and other relevant outcomes in these diseases.
Interviews with the EMEA conﬁrmed that, in the
absence of a general guidance document on the use
of HRQL and PROs or in the development of new
guidelines, disease-group level review and recom-
mendations are dependent on the experience of the
EMEA and the views of the individual experts. In
addition, HRQL or other PRO data may be submit-
ted by the manufacturer and considered by the
EMEA whether or not the relevant EMEA/CHMP
recommendation explicitly mentions these end-
points. If HRQL or other PRO data are submitted
for drugs where the relevant EMEA/CHMP recom-
mendation does not explicitly mention these as
possible endpoints, the EMEA still considers them.
Table 1 HRQL and other PRO data in guidance documents published by the European Agency for the Evaluation of Medicinal
Products (EMEA), 1995–2003
Document HRQL and other PROs included Year† HRQL and other PROs not included Year†
Concept Sepsis* 2003 Ankylosing spondylitis 2003
papers Social anxiety disorder* 2003 Chemotherapy-induced nausea and vomiting
Chronic hepatitis B
Dyslipoproteinemia
Peptides and proteins
2003
2003
2001
2002
Points to Acute stroke 1998 Acute coronary syndrome 1998
consider Amyotrophic lateral sclerosis 1998 Acute respiratory distress syndrome 1997
COPD 1998 Antifungal agents 2001
Crohn’s disease 1999 Diagnostic agents 1998
Irritable bowel syndrome 1997 Hemoatopoietic growth factors 1999
Neuropathic pain 2003 Hormone replacement therapy 1997
Osteoarthritis 1997 Prophylaxis of intra- and postoperative 
venous thromboembolic risk
1998
Rheumatoid arthritis 1995
Guidelines—
draft
Anxiety disorder (draft)
Allergic Rhinoconjunctivitis (draft)
2002
2002
Impaired hepatic function (draft) 2002
Obsessive compulsive disorder draft) 2002
Panic disorder (draft) 2002
Psoriasis (draft) 2002
Guidelines—
adapted
Asthma
Acute cardiac failure*
2001
2001
Antibacterial medicinal products
Bipolar disorder
1995
1998
Alzheimer’s disease 1995 Depression 1997
Antiarrhythmics* 1995 Diabetes mellitus 2000
Cancer 1995 Epileptic disorders 1998
Cardiac failure 2003 Hypertension 1995
HIV infection 2002 Impaired renal function 2002
Migrain 2001 Lipid disorders 2003
Multiple sclerosis 1998 New vaccines 1997
Nociceptive pain 2000 Post menopausal osteoporosis in women 1995
Parkinson’s disease 1995 Schizophrenia 2001
Peripheral arterial occlusive disease (PAOD) 1998 Steroid contraceptives in women 1998
Urinary incontinence 2001 Thromboembolic disease 1998
Stable angina pectoris 1995 Thrombosis in acute myocardial infarction 2001
Weight control 1996
No. issued 30 (53%) 27 (47%)
*HRQL cited as an important aspect of the disease or treatment, but no explicit recommendations are made on the inclusion of HRQL measurement in clinical trials.
†Year of ﬁrst version issued.
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The importance of HRQL or other PRO data in the
review and decision-making process is based on its
relevance to a particular drug and study according
to the judgment of the CHMP.
Discussion of HRQL and other PROs as efﬁcacy
endpoints. Table 2 presents a summary of key
issues related to HRQL and other PRO data pre-
sented in the disease-group level guidance docu-
ments [11–38]. Because reference to sepsis, social
anxiety disorder, antiarrhythmics, and acute cardiac
failure did not include speciﬁc recommendations,
these documents are excluded from the table. All
but three of the guidelines addressed HRQL. In 15
cases, recommendations included PROs or speciﬁc
HRQL domains, namely, patient-reported symp-
toms, discomfort, pain, disability, physical func-
tioning, general well-being, and patient’s global
assessment of improvement. Most of the guidelines
regarded HRQL or PROs data as potential efﬁcacy
endpoints but the guidance on HIV medication
recommended that HRQL data can serve as an
additional safety endpoint.
Ten (38%) of these guidance documents sug-
gested that HRQL or other PROs can be considered
either primary or secondary endpoints. These doc-
uments addressed submissions in the areas of aller-
gic rhinoconjuctivitis, cancer, chronic obstructive
pulmonary disease (COPD), irritable bowel syn-
drome (IBS), osteoarthritis, pain, Parkinson’s dis-
ease, rheumatoid arthritis, stable angina pectoris,
and neuropathic pain. Three of these guidance doc-
uments (i.e., rheumatoid arthritis, cancer, and stable
angina pectoris) recommended HRQL among pos-
sible primary endpoints. The document on COPD
advised that symptomatic beneﬁt serve as a copri-
mary endpoint (with lung function) while HRQL
serve as a secondary endpoint. The St George’s
Respiratory Questionnaire (SGRQ), which is
commonly used as a condition-speciﬁc indicator of
HRQL in this population, was mentioned as an
example of a symptom outcome measure. Inter-
views with the EMEA pointed out that guidance
documents offer recommendations, rather than
mandates, leaving open the possibility that HRQL
and other PRO outcomes can serve as a primary
endpoint, provided that there is a strong rationale
and that the instrument selection is justiﬁed.
Reference to speciﬁc HRQL and other PRO
measures. Most of the guidance documents did not
specify whether generic or condition-speciﬁc in-
struments should be used to evaluate HRQL. The
guidance document on peripheral arterial occlusive
disease suggested that HRQL “be measured by
properly validated generic and disease-speciﬁc ques-
tionnaires,” while the document on amyotrophic
lateral sclerosis (ALS) indicated that if generic
HRQL measures are used they should be validated
in ALS patients. The need for valid disease-speciﬁc
HRQL measures was also highlighted in the guid-
ance documents related to Alzheimer’s disease (AD).
The guidelines for AD indicate that no speciﬁc tool
can be recommended. The exact wording is as
follows: “Although quality of life is an important
dimension of the consequences of diseases, the lack
Table 2 Health-related quality of life (HRQL) and other patient-reported outcomes in disease-group level guidance docu-
ments issued by the European Agency for the Evaluation of Medicinal Products (EMEA), 1995–2003
Disease group
Recommended primary
clinical endpoints
Recommended HRQL and
other PROs
Mention of example 
instrument
Points to consider
Acute stroke Survival; disability group HRQL N/A
Amyotrophic
lateral sclerosis
Survival; Muscle strength; Respiratory 
function; Functional test of disability
HRQL N/A
COPD Lung function; Symptomatic beneﬁt HRQL; patient-reported symptoms St. George’s Respiratory 
Questionnaire, SGRQ
Crohn’s disease Proportion of patients achieving/maintaining 
remission
HRQL Inﬂammatory Bowel Disease 
Questionnaire, IBDQ
Irritable bowel
syndrome
Patient’s global assessment of symptoms;
Abdominal pain and discomfort
HRQL; patient-reported symptoms,
pain and discomfort
N/A
Neuropathic pain Multidimensional, patient-rated, pain 
assessment
HRQL; Patient-reported pain; 
Patients’ global assessment; 
Functional performance; Social 
performance
McGill Pain Questionnaire (MPQ);
MPQ Short Form (MPQ-SF); 
Neuropathic Pain Scale (NPS)
Osteoarthritis Pain and functional disability HRQL; patient-reported pain and 
disability
Western Ontario McMaster 
University, WOMAC
Rheumatoid 
arthritis
Joint count (swollen or painful); disease 
activity (assessed by the physician or 
patient); pain score (patient’s assessment
of ain, VAS); acute phase reactants, 
physical function and HRQL; radiograph
HRQL; patient-reported pain, 
physical functioning
Health Assessment Questionnaire 
(HAQ), Arthritis Impact 
Measurement Scale (AIMS), SF-
36 Health Survey
(continued)
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of validation of its assessment in AD does not allow
speciﬁc recommendations to be made as yet. When
adequate instruments to assess this dimension in pa-
tients and their care givers become available, quality
of life assessment may be justiﬁed in AD trials.”
Wherever an HRQL or another PRO measure
was mentioned as an example in the guidance
documents, it was always a condition-speciﬁc
instrument. The only exception was the guidance
on rheumatoid arthritis which mentioned the
Guidelines
Allergic Rhino-
conjunctivitis
(draft)
Patient-rated symptoms Patient-rated symptoms N/A
Alzheimer disease Cognition; ADL; Overall clinical response HRQL N/A
Asthma Airway obstruction; lung function; 
symptom-based clinical endpoints
HRQL N/A
Cancer Tumor burden; disease stabilization/
prolonged progression-free survival, and 
overall survival; Progression-free 
recurrence-free/relapse-free survival; 
Response rate; Symptom control/HRQL
HRQL N/A
Cardiac failure
(acute and 
chronic)
Mortality; Clinical symptoms (chronic 
cardiac failure)
HRQL; Self-assessed global clinical 
status; Patient-rated symptomatic 
improvements in dyspnea, fatigue, 
mental confusion, and general 
well-being
Minnesota Living with Heart 
Failure Questionnaire
General anxiety
disorder (draft)
Hamilton Anxiety Rating Scale (HAM-A) Self-assessed disability; HRQL Sheenan Disability Scale
HIV infection Viral load and CD4+ T-cell counts HRQL N/A
Migraine Percent of patients pain-free at 2 h after 
administration of medication
HRQL; Global evaluation of 
medication by patient
N/A
Multiple sclerosis Duration and severity of relapses (acute 
treatment); Disability progression 
(disease modifying treatment)
HRQL; “Patient’s global opinion” N/A
Obsessive 
compulsive 
disorder
Yale-Brown Obsessive Compulsive Scale
(Y-BOCS)
Global self-assessed scales to 
measure social and occupational 
functioning
Sheenan Disability Scale
Pain Self-assessed pain Multidimensional 
assessment tools
Self-assessed pain Multidimensional 
assessment tools
Visual Analog Scale (VAS); 
Numerical Pain Scale (NPS); Pain 
Descriptor Scales (PDS); McGill 
Pain Questionnaire; Short Form 
McGill Pain Questionnaire; 
Minnesota Multiphasic 
Personality Inventory; 
Psychological Pain Inventory; 
McGill Comprehensive Pain 
Questionnaire; Pain Proﬁle; 
Multidimensional Pain Inventory
Panic disorder
(draft)
Frequency and severity of attacks; Panic 
Disorder Severity Scale (PDSS); Panic and 
Agoraphobia Scale (PAS)
Self-assessed disability; HRQL Sheenan Disability Scale
Parkinson’s 
disease
Success and failure to treat symptoms 
measured by various rating scales 
depending on the treatment objectives
HRQL N/A
Peripheral arterial
occlusive 
disease
Initial and absolute claudication distance 
(stage I); pain at rest and response-based
endpoints (stage II); ulcer healing and 
response-based endpoints (stage IV)
HRQL N/A
Psoriasis (draft) Psoriasis area and severity index (PASI); 
visual assessment of index lesions, BSA 
measurement, total severity sign score 
(TSS); physicians’ global assessment 
(PGA) of all lesions on a 6- or 7-point 
scale
Patient’s assessment of global 
improvement (same as PGA but 
responded by patient); self-
administered PASI (SAPASI); 
HRQL scales validated in 
dermatology
Dermatology Life Quality Index 
(DLQI); Dermatology Quality of 
Life Scales (DQLS); Skindex; 
Psoriasis Disability Index (PDI), 
Psoriasis Life Stress Inventory 
(PLSI)
Stable angina
pectoris
Exercise capacity; anginal pain; HRQL; 
morbidity and mortality; and ischemic 
pisodes
HRQL N/A
Urinary 
incontinence
Urodynamic endpoints HRQL; Patient-rated symptoms N/A
Weight control Demonstrated weight loss HRQL N/A
Disease group
Recommended primary
clinical endpoints
Recommended HRQL and
other PROs
Mention of example 
instrument
Table 2 continued
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generic SF-36 Health Survey instrument as an
example.
Only the guidelines on urinary incontinence
addressed the issue of how HRQL information
should appear in the SPC. This guidance document
suggested that if clinically relevant changes were
found in HRQL data, they should be included in the
pharmacodynamics section of the SPC, the section
generally containing efﬁcacy data.
The interviews conﬁrmed that instruments men-
tioned in disease-related EMEA/CHMP recommen-
dations serve as examples only, should not be
construed as an endorsement by the EMEA, and
therefore do not preclude the use of other measures.
Pharmaceutical industry investigators are encour-
aged to use well-developed and validated outcome
measures. Any clinical trial with HRQL and PRO
outcomes to be submitted for consideration by the
EMEA should have prespeciﬁed hypotheses, well-
designed study protocols, planned statistical analy-
ses, and careful implementation.
Product-Level Information
Scientiﬁc discussion. According to the EPAR docu-
ments, 237 products were registered by the EMEA
from 1995 to 2003. The systematic search identiﬁed
81 (34% of those submitted) products that included
HRQL or other PRO information (Table 3).
In the majority of cases (i.e., 55), the PROs used
to evaluate these products were various kinds of
HRQL outcomes. In 46 cases, PROs other than (or
in addition to) HRQL outcomes were reported.
PROs other than HRQL included, patient-reported
symptoms, functional status, pain, disability,
bother, patient preference, patient satisfaction with
treatment, and patient’s global assessment.
A subgroup analysis was performed on the Ana-
tomical-Therapeutic-Clinical (ATC) groups reﬂect-
ing those 67 products that had different active
ingredients or had the same active ingredients but
had different therapeutic indications, forms, or
manufacturer (14 out of the 81 products were iden-
tical but were registered under different trademark
names). As Figure 1 reveals, the most prominent
disease areas where HRQL and other PROs were
included in the drug evaluation were antineoplastic
and immunomodulating agents, mainly involving
cancer products.
The Scientiﬁc Discussions varied in the level of
detail provided on the HRQL and other PRO out-
comes. Speciﬁcation of these variables as primary or
secondary trial endpoints was not always clearly
stated in the Scientiﬁc Discussion document. Based
on the information available, these outcomes were
generally included as secondary efﬁcacy endpoints.
PROs appeared as primary endpoints mainly in
those cases where they were the only possible pri-
mary efﬁcacy parameters, for example, self-assessed
pain or the effectiveness of treatment of erectile
dysfunction.
In 24 of the 81 Scientiﬁc Discussions (30%), the
speciﬁc HRQL or other PRO instrument used was
not mentioned. The Scientiﬁc Discussion simply
referred to the results, for example, as “quality of
life” or “patient satisfaction” data. There was a ten-
dency not to specify the instrument if HRQL results
did not differ signiﬁcantly between the treatment
groups. The majority of the reported clinical trials
used condition-speciﬁc instruments to measure
HRQL outcomes. The only generic instrument used
more than once was the SF-36 Health Survey. The
SF-36 was used in the evaluation of drugs for the
treatment of rhinitis, rheumatoid arthritis, popypo-
sis, Fabry disease, cancer and chronic hepatitis C.
The SF-36 was most often used along with a
disease-speciﬁc HRQL or other PRO instrument.
In the case of rhinitis and cancer, results using
condition-speciﬁc instruments paralleled results
using the SF-36. In the case of Fabry disease, the
drug Fabrazyme did not show statistically sig-
niﬁcant improvements on the SF-36 scores but
signiﬁcant results were detected on McGill Pain
Questionnaire. Preference-based measures, the EQ-
5D and the Health Utility Index, were reportedly
used for Humira and Taxotere, but the documents
did not include sufﬁcient information to judge the
role of these data in evaluating the effectiveness of
the product. The appearance of HRQL and other
PRO data in the Scientiﬁc Discussion of products
indicated for the treatment of cancer, osteoarthritis,
Figure 1 The relative share of products in different ATC drug
groups of all products with HRQL and other PRO data in regulatory
documents.
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Table 3 Pharmaceutical products registered with the European Agency for the Evaluation of Medicinal Products (EMEA) with
health-related quality of life (HRQL) and other Patient-Reported Outcomes (r-PRO) in the scientiﬁc discussion, 1995–2003
Product Generic name Indication HRQL or other PRO instrument
Aerius* Desloratadine Rhinitis SF-36 Health Survey, rhinoconjunctivitis QoL questionnaire
Aldurazyme* Laronidase Enzyme replacement therapy
in mucopolysaccharodosis I
Health Assessment Questionnaire (HAQ), Apnea Hypopnea Index 
(AHI)
Allex* Desloratadine Rhinitis SF-36 Health Survey, rhinoconjunctivitis QoL questionnaire
Arava Leﬂunomide Rheumatoid arthritis Health Assessment Questionnaire
Azomyr* Desloratadine Rhinitis SF-36 Health Survey, rhinoconjunctivitis QoL questionnaire
Bextra* Valdecoxib Ostheoarthritis, rheumatoid 
arthritis, primary 
dysmenorrhea
Western Ontario and McMaster Universities (WOMAC) OA Pain 
Index and OA Physical Function Index, Patient’s Global Assessment 
of  Arthritis, Patient’s Overall Assessment of Pain measured by Visual 
Analog Scale (VAS), Patient’s Global Assessment of Disease Activity, 
Modiﬁed Health Assessment Questionnaire Disability Index (mHAQ)
Caelyx Doxorubicin
Hydrochloride
AIDS-related Kaposi’s 
sarcoma
MOS-HIV Health Survey
Cialis* Tadalaﬁl Erectile dysfunction Sexual Encounter Proﬁle, International Index of Erectile Dysfunction
Comtess Entacapone Parkinson’s disease ON/OFF period assessment based on patient symptom diary
Comtan Entacapone Parkinson’s disease ON/OFF period assessment based on patient symptom diary
Cotronak Ribavirin Hepatitis C Unspeciﬁed HRQL measure
Depocyte* Cytarabine Lymphomatus meningitis Fact-CNS
Dynastat Parecoxib Postoperative pain Pain Intensity Difference questionnaire
Emadine Emedastine Seasonal allergic conjunctivitis A nine-point symptom assessment patient diary scale
Emend Aprepitant Prevention of nausea and 
vomiting associated with 
cancer chemotherapy
Functional Living Index—Emesis
Exelon Rivastigmine Alzheimer’s dementia Progressive Deterioration Scale
Enbrel Etanercept Rheumatoid arthritis SF-36 Health Survey, Health Assessment Questionnaire
EVRA Norelgestromin 
and ethinyl 
estradiol
Female contraception Unspeciﬁed scale to measure patient satisfaction
Fabrazyme* Agalsidase beta Fabry disease SF-36 Health Survey, McGill Pain Questionnaire
Foscan Temoporﬁn Cancer Washington University Head and Neck Questionnaire
Fuzeon Enfuvirtide HIV-1 Subcutanous Injection Survey
Herceptin Trastuzumab Cancer European Organization for Research on Treatment of Cancer QLQ 
(EORTC)
Humalog Insulin lispro Diabetes Unspeciﬁed HRQL and patient satisfaction measure
Humira* Adalimumab Rheumatoid arthritis Health Assessment Questionnaire (HAQ), Functional Assessment of 
Chronic Illness Therapy—Fatigue Scale (FACIT-F), 
Multidimensional Assessment of Fatigue (MAF), SF-36 Health 
Survey, EQ-5D, Health Utility Index
Hycamtin Topotecan Cancer European Organization for Research on Treatment of Cancer QLQ 
(EORTC)
Insulatard Insulin human
rDNA
Diabetes Unspeciﬁed HRQL and patient satisfaction measure
Intron A Interferon alfa-
2b
Hepatitis, Cancer Unspeciﬁed HRQL instrument
Ixense* Apomorphine
hydrochloride
Erectile dysfunction International Index of Erectile Dysfunction, Brief Sexual Function 
Inventory
Keppra Levetiracetam Epilepsy Unspeciﬁed HRQL instrument
Kineret Anakinra Rheumatoid arthritis Health Assessment Questionnaire
Kudeq* Valdecoxib Ostheoarthritis, rheumatoid 
arthritis, primary 
dysmenorrhea
Western Ontario and McMaster Universities (WOMAC) OA Pain 
Index and OA Physical Function Index, Patient’s Global Assessment 
of Arthritis, Patient’s Overall Assessment of Pain measured by Visual 
Analog Scale (VAS), Patient’s Global Assessment of Disease Activity, 
Modiﬁed Health Assessment Questionnaire Disability Index (mHAQ)
Lantus Insulin glargine Diabetes Diabetes Treatment Satisfaction Questionnaire and Well-Being 
Questionnaire
Levitra* Vardenaﬁl Erectile dysfunction International Index of Erectile Function (IIEF), question 2 and 3 of the 
Sexual Encounter Proﬁle, a single-item self-reported global 
assessment question, Fugl-Meyer Quality of Life Questionnaire, 
Center for Epidemiological Studies Depression Scale (CES-D)
Liprolog Insulin lispro Diabetes Unspeciﬁed HRQL and patient preference measurement
Lumigan Bimatoprost Chronic open-angle glaucoma 
and ocular hypertension
Unspeciﬁed patient satisfaction questionnaire
Myocet Doxorubicin Cancer European Organization for Research on Treatment of Cancer QLQ 
(EORTC)
Neoclarityn* Desloratadine Rhinitis SF-36 Health Survey, rhinoconjunctivitis QoL questionnaire
Neorecormon Epoetin beta Renal failure Unspeciﬁed HRQL instrument
Neurobloc Botulinum toxin
type B
Cervical dystonia Patient’s Global Assessment, self-assessed pain measures
Norvir Ritonavir HIV Three different unspeciﬁed HRQL instruments and Karnofsky 
Performance Scale
NutropinAQ Somatropin Growth failure Unspeciﬁed HRQL instrument
Onsenal Celecoxib Familial adenomatous 
polyposis
SF-36 Health Survey
(continued)
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Opatanol Olopatadine Seasonal allergic conjuctivitis Unspeciﬁed HRQL instrument
Optisulin Insulin glargine Diabetes Diabetes Treatment Satisfaction Questionnaire and Well-Being 
Questionnaire
Opulis* Desloratadine Rhinitis SF-36 Health Survey, Rhinoconjunctivitis QoL Questionnaire
Panretin Alitretionin Kaposi’s sarcoma Unspeciﬁed HRQL instrument
Patrex* Sildenaﬁl Erectile dysfunction International Index of Erectile Function and unspeciﬁed HRQL 
questionnaire
Paxane Paclitaxel AIDS-related Kaposi’s 
sarcoma
Symptom Distress Scale, Karnofsky Performance Score
Pegasys Peginterferon
alfa-2a
Chronic hepatitis C SF-36 Health Survey, Fatigue Severity Scale
PegIntron* Peginterferon
alfa-2b
Hepatitis C SF-36 Health Survey
Prothapane Insulin human
rDNA
Diabetes mellitus Unspeciﬁed HRQL and overall treatment satisfaction measure
Protopic Tacrolimus Atopic dermatitis Dermatology Life Quality Index
Protopy Tacrolimus Atopic dermatitis Dermatology Life Quality Index
Rayzon Parecoxib Postoperative pain Pain Intensity Difference questionnaire
Rebetol Ribavirin Hepatitis C Unspeciﬁed HRQL measure
Rebif Interferon
beta-1a
HIV-1 General Health Questionnaire, Epidemiologic Depression Mood Scale 
(CES-D), Beck Hopelessness Scale
Remicade Inﬂiximab Crohn’s disease Inﬂammatory Bowel Disease Questionnaire, IBDQ, Health Assessment 
Questionnaire, HAQ
Somavert Pegvisomant Acromegaly Unspeciﬁed HRQL measure
Stalevo Levodopa/
Carbidopa/
Entacapone
Parkinson’s disease Patient preference for treatment
Stocrin Efavirenz HIV MOS-HIV Health Survey, Karnofsy scale
Sustiva Efavirenz HIV MOS-HIV Health Survey, Karnofsy scale
Taluvian* Apomorphine
hydrochloride
Erectile dysfunction International Index of Erectile Dysfunction, Brief Sexual Function 
Inventory
Taxotere* Docetaxel Cancer EQ-5D, Karnofsky performance status, Lung Cancer Symptom Scale, 
European Organization for Research on Treatment of Cancer QLQ 
(EORTC)
Temodal* Temozolomide Cancer Unspeciﬁed HRQL measure
Thyrogen* Thyrotropin alfa Cancer SF-36 Health Survey, Proﬁle Mood States
Tikosyn* Dofetilide Atrial ﬁbrillation Unspeciﬁed HRQL instrument
Trudexa* Adalimumab Rheumatoid arthritis Health Assessment Questionnaire (HAQ), Functional Assessment of 
Chronic Illness Therapy—Fatigue Scale (FACIT-F), Multidimensional 
Assessment of Fatigue (MAF), SF-36 Health Survey, EQ-5D, Health 
Utility Index
Uprima* Apomorphine
hydrochloride
Erectile dysfunction International Index of Erectile Dysfunction, Brief Sexual Function 
Inventory
Valdyn Valdecoxib Ostheoarthritis,
rheumatoid arthritis,
primary dysmenorrhea
Western Ontario and McMaster Universities (WOMAC) OA Pain 
Index and OA Physical Function Index, Patient’s Global Assessment 
of Arthritis, Patient’s Overall Assessment of Pain measured by Visual 
Analog Scale (VAS), Patient’s Global Assessment of Disease Activity, 
Modiﬁed Health Assessment Questionnaire Disability Index (mHAQ)
Vaniqa* Eﬂornithine Dermatology Subjects Self-Assessment Questionnaire (an instrument with six 
questions each rated by a 10 cm visual analog scale)
Ventavis Iloprost Primary pulmonary
hypertension
Unspeciﬁed HRQL instrument
Viagra* Sildenaﬁl Erectile dysfunction International Index of Erectile Function, Global Assessment Question, 
Partner Questionnaire, and an unspeciﬁed HRQL questionnaire
Viracept Nelﬁnavir HIV Karnofsky Performance Scale
Viraferon Interferon alfa-
2b
Hepatitis B and C Unspeciﬁed HRQL instrument
ViraferonPeg Peginterferon
alfa-2b
Hepatitis C SF-36 Health Survey
Vivanza* Vardenaﬁl Erectile dysfunction International Index of Erectile Function (IIEF), question 2 and 3 of the 
Sexual Encounter Proﬁle, a single-item self-reported global 
assessment question, Fugl-Meyer Quality of Life Questionnaire, 
Center for Epidemiological Studies Depression Scale (CES-D)
Xeloda Capecitabine Cancer European Organization for Research on Treatment of Cancer QLQ 
(EORTC)
Xenical Orlistat Obesity Patient rated distress, depression, self-regard, and satisfaction with 
treatment
Zavesca Miglustat Type 1 Gaucher disease Unspeciﬁed HRQL instrument
Zyprexa Olanzapine Schizophrenia Quality of Life Scale
Zyprexa Velotab Olanzapine Schizophrenia Quality of Life Scale
Product Generic name Indication HRQL or other PRO instrument
Table 3 continued
*PRO data also is included in the SPC document.
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rheumatoid arthritis, Parkinson’s disease, Crohn’s
disease, and obesity were consistent with EMEA/
CHMP recommendations. The remaining products
were reviewed and approved with HRQL and other
PRO data in the absence of any speciﬁc disease-
group level recommendations. These results were
consistent with interview data suggesting that the
EMEA will consider HRQL (or other type of PRO)
data submitted in support of drugs where the
relevant EMEA/CHMP recommendation does not
explicitly mention these endpoints.
Summary  of  product  characteristics. Of the 81
products with HRQL or other PRO data in the
Scientiﬁc Discussion, 26 (32%) included these
results in the SPC document. With the exception of
Aldurazyme, Depocyte and Taxotere, SPCs included
HRQL or other PRO data only if the results were
statistically signiﬁcant. In the case of Taxotere,
equivalent HRQL outcomes across treatment
groups were interpreted as a positive outcome, an
indication that treatment did not adversely affect
patient HRQL. In general, HRQL data were
presented very brieﬂy, without speciﬁc results or
domain level information. The only exception was
the SPC of Humira (also registered as Trudexa) that
contained more detailed information on PRO
instruments used and results observed on different
subscales of these instruments:
Health-related quality of life and physical func-
tion was assessed using the disability index of the
Health Assessment Questionnaire (HAQ) in all
four adequate and well-controlled trials, which
was a prespeciﬁed primary endpoint at week 52
in Study III. All doses/schedules of Trudexa in all
four studies showed statistically signiﬁcantly
greater improvement in the disability index of the
HAQ from baseline to Month 6 compared to pla-
cebo and in Study III the same was seen at Week
52. Results from the Short Form Health Survey
(SF 36) for all doses/schedules of Trudexa in all
four studies support these ﬁndings, with statisti-
cally signiﬁcant physical component summary
(PCS) scores, as well as statistically signiﬁcant
pain and vitality domain scores for the 40 mg
every other week dose. A statistically signiﬁcant
decrease in fatigue as measured by functional
assessment of chronic illness therapy (FACIT)
scores was seen in all three studies in which it
was assessed (Studies I, II, IV).
Package  leaﬂet. Only products containing the
active substance desloratadine included information
on HRQL or other PRO effects of treatment in the
package leaﬂets. This could be due to the fact that
package leaﬂets approved by the EMEA focus on
mainly on safety issues, usage, side effects, and stor-
age information, rather than efﬁcacy data.
As the following paragraph illustrates, the pack-
age leaﬂet for Aerius (desloratadine) included infor-
mation from the ﬁndings of the rhinoconjunctivitis-
speciﬁc HRQL measurement (activities, sleep) used
in the clinical trials:
What Aerius is and what it is used for
. . . Aerius is an antiallergy medicine that does
not make you drowsy. It helps control your aller-
gic reaction and its symptoms. Aerius relieves
symptoms associated with seasonal allergic rhin-
itis (for example, hay fever) such as sneezing,
runny or itchy nose, itchy palate, and itchy, red
or tearing eyes. Aerius is also used to relieve the
symptoms associated with chronic idiopathic
urticaria such as itching and hives.
Relief of these symptoms lasts a full day and
helps you to resume your normal daily activities
and sleep.
Abstracts. Eight products included reference to
HRQL and other PRO data in their abstracts. Five
of these contained the active substance of deslorat-
adine and were indicated for the treatment of rhin-
itis. The remaining three products were Caelyx
indicated for the treatment of AIDS-related Kaposi’s
sarcoma, Depocyte for the treatment of lymphom-
atus meningitis, and Thyrogen used in thyroid can-
cer patients.
The abstract for Depocyte included a statement
on potential quality of life improvement (due to the
ease of administration) that was not supported by
the HRQL evidence introduced in the Scientiﬁc Dis-
cussion. The abstract stated: “Depocyte has a more
convenient schedule of administration compared to
conventional ara-C as it reduces the need for mul-
tiple injections and this may impact quality of life
favorably.” The Scientiﬁc Discussion and the SPC
indicated HRQL outcomes were compared between
the two groups and no differences were found. It
was unclear, however, if the term “quality of life”
was used in the same meaning across the SPC and
the abstract.
Products containing desloratadine appeared to
be the only case in which the Scientiﬁc Discussion,
the SPC, the package leaﬂet, and the abstract all
included some of the HRQL and other PRO results.
Numeric Summary
The development of disease-speciﬁc instruments
and new research and statistical methods for HRQL
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and PRO evaluation is a rapidly developing
research area. Therefore, a relevant question is
whether there is any indication of an increasing role
that these health outcomes play in the drug regula-
tory process. Temporal trends involving recommen-
dations on HRQL and PRO data in EMEA/CHMP
guidance documents is as yet difﬁcult to judge
because these documents have been developed and
repeatedly revised over the past 9 years of the oper-
ation of the EMEA. Regarding the authorization of
pharmaceutical products, Figure 2 illustrates that
with the increase of registered products, the number
of products with HRQL and other PRO data in
their regulatory documents also increased and
exceeded 30% in the last 4 years (between 1999
and 2003).
Discussion and Conclusions
The review revealed that although no general regu-
latory guidance documents have been issued for
HRQL and other PRO evaluation by the EMEA,
more than half of the EMEA/CHMP guidance doc-
uments on clinical investigation of pharmaceutical
products in speciﬁc disease areas include reference
to, or recommendations on, these outcomes. Even
in the absence of general or disease-speciﬁc guid-
ance, HRQL and other PRO data appeared in the
Scientiﬁc Discussions of 34% of the products sub-
mitted between 1995 and 2003. Claims appeared in
the SPCs of some of the products but relatively little
detail or information is included in the SPC. These
descriptive ﬁndings should be carefully interpreted
within the light of the evolving European regulatory
environment and current measurement and meth-
odological developments within the HRQL research
ﬁeld.
During the past decade, independent health out-
comes researchers in Europe and North America
have outlined recommendations on HRQL evalua-
tion for drug regulatory purposes [5,39–42].
Although these recommendations have played an
important role in setting standards for good science
in HRQL research, they did not constitute the ofﬁ-
cial opinion of any regulatory authorities. The
direct adaptation of these scientiﬁc recommenda-
tions by a regulatory body like the EMEA would
not have been easily feasible, not least because of
the variations reﬂected across them in some concep-
tual and methodological issues such as the deﬁni-
tion of HRQL. As the interviews with the EMEA
representatives conﬁrmed, it would have been difﬁ-
cult for a regulatory authority to develop prescrip-
tive guidelines for an outcomes research community
which is characterized by ongoing debates on
important research issues.
Historically, the rapidly evolving HRQL research
environment have been an contributing factor to the
lack of an ofﬁcial harmonized approach for consid-
ering HRQL outcomes in the newly created central-
ized European regulatory review process. Because
of a lack of a speciﬁed EMEA guidance documents,
decisions on considering HRQL data during
authorizations were delegated to EMEA appointed
committees consisting of external experts with var-
ying degrees of experience and expertise in HRQL
or other PRO research. The potential inclusion of
HRQL and other PRO data in ofﬁcial guidance doc-
uments on regulatory clinical trials for each disease
area has been dependent on individual experts’
views and knowledge about HRQL and PRO
research who have been involved in the drafting and
approval of guidance documents. This has lead to
variations and inconsistencies in recommendations,
in terms of positioning HRQL and other PRO data
among study endpoints, requirements on psycho-
metric standards, analytical requirements, and
other aspects of HRQL evaluation.
On the other hand, our review of performed
authorizations revealed that, despite these uncer-
tainties in published recommendations on HRQL
and other PRO data, manufacturers opted to collect
and submit HRQL and PRO data in their clinical
trials and regulatory ﬁlings. The appearance of
these data in the approved regulatory documents of
these products reﬂected the EMEA’s approach that
all HRQL and PRO data can be considered, given
that the data inclusion is justiﬁed and the scientiﬁc
methods used were rigorous. The continued appli-
Figure 2 The number of registered different drugs and number of
HRQL or other PRO data in regulatory documents. Note: “Different
drug” means those drugs that have different active agent or those that
include the same active agent but have different therapeutic indica-
tion. Multiple registered drugs with identical active agent and identical
therapeutic indication were counted only once.
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cation of HRQL and PROs in industry sponsored
research is driven by the need to demonstrate dif-
ferentiation among competing products and in dem-
onstrating value in terms of patient health outcomes
relative to expenditures.
An important area for the more efﬁcient use and
communication of HRQL and other PRO data
would be to better deﬁne the optimal role of HRQL
and PRO data in the published regulatory docu-
ments of pharmaceutical products. The purpose of
the Scientiﬁc Discussion is to reﬂect how authoriza-
tion decisions were made and what evidence they
were based on. Nevertheless, currently it is not
transparent how submitted HRQL and PRO infor-
mation is screened, considered, and abstracted into
the Scientiﬁc Discussion document. Because of the
lack of publicly available information on the screen-
ing process, it is unclear from the review of docu-
mentation from the EMEA/CHMP how judgments
are made regarding the quality of PRO measures
that are used in clinical trials. It would seem that
results from different measures are taken mainly at
face value without thorough review of the validity
and reliability of different measures. It is also not
clear how judgments are made about the translation
and cultural adaptation process that is required to
use PROs in different countries.
The objective of the SPC and the Package Leaﬂet
is to inform physicians and patients about the med-
ication. According to the current regulations, safety
information has priority over efﬁcacy data and the
avoidance of any potential promotional use of
information [43]. No efﬁcacy data is generally
expected in the SPC and no efﬁcacy data is allowed
in the Package Leaﬂet apart from exceptional cases.
Our review revealed no clear tendency for HRQL
and other PRO data that are regarded as sufﬁciently
important to be included in the SPC and the Pack-
age Leaﬂet.
Finally, the results of this review suggest that
there is some evidence for the varying use of
HRQL and other PRO information in the regula-
tory process across disease groups. There are areas,
cancer in particular, where ofﬁcial recommenda-
tions suggest a potentially important role for
HRQL data and a high proportion of the submit-
ted regulatory applications in oncology include
these PROs. On the other hand, in several disease
areas with well-established HRQL research and
instruments, ofﬁcial recommendations lack refer-
ence to HRQL and other PRO data and regulatory
documents also suggest the lack of consideration of
this important aspect of the treatment in the regu-
latory process.
Health outcomes researchers view HRQL and
other PRO data as useful in understanding the
impact of disease and treatment on patient out-
comes. These outcomes data can assist physicians
and their patients in safe and effective treatments.
The application of these health outcome measures
should not be dependent on uncertain factors, such
as lack of understanding between health outcomes
researchers and regulatory decision-makers. Health
outcomes researchers should provide evidence for
including HRQL data in clinical trials, highlight the
added value of HRQL results to the clinical data for
the regulatory decision-makers, and should, in gen-
eral, follow good scientiﬁc methods for the design,
conduct and analysis of clinical trial data. The reg-
ulatory decision-makers could better communicate
their evaluation standards and process related to
HRQL data and develops and updates harmonized
procedures and expertise to adequately appraise
and  use  the  HRQL  and  other  PRO  information
in  the  regulatory  decision-making  process.  The
just recently released reﬂection paper on HRQL
research by the EMEA and its currently ongoing
public debate is a promising step towards achieving
this aim [44].
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